Burning Rock Biotech Ltd 6-K, filed Sep 10, 2026

Burning Rock Biotech Ltd (BNR)

6-K 2026-09-10 For: 2026-09-10

View Original

Added on September 10, 2026

About this 6-K

Burning Rock Biotech Ltd filed this 6-K on September 10, 2026.

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


Number		Description of Document

Exhibit 99.1		Press release


	Burning Rock Biotech Limited

	By:	/s/ Yusheng Han
	Name:	Yusheng Han
	Title:	Chief Executive officer
Date: September 10, 2026


	As of
	June 30, 2025		September 30, 2025		December 31, 2025		March 31, 2026		June 30, 2026
In-hospital channel:
Pipeline partner hospitals⁽¹⁾		30		31		30		30		30
Contracted partner hospitals⁽²⁾		63		63		64		64		64
Total number of partner hospitals		93		94		94		94		94


	For the three months ended
Revenues	June 30, 2025		September 30, 2025		December 31, 2025		March 31, 2026		June 30, 2026
			(RMB in thousands)
Central laboratory channel		40,861		36,811		44,025		32,420		36,782
In-hospital channel		62,496		52,847		51,005		52,761		67,145
Pharma research and development channel		45,197		41,959		31,285		22,762		30,838
Total revenues		148,554		131,617		126,315		107,943		134,765


	For the three months ended
Gross profit	June 30, 2025		September 30, 2025		December 31, 2025		March 31, 2026		June 30, 2026
			(RMB in thousands)
Central laboratory channel		35,937		30,126		39,322		28,761		31,510
In-hospital channel		46,490		37,925		38,388		38,458		51,760
Pharma research and development channel		25,676		30,793		20,856		10,789		14,543
Total gross profit		108,103		98,844		98,566		78,008		97,813


	For the three months ended
Share-based compensation expenses	June 30, 2025			September 30, 2025		December 31, 2025		March 31, 2026			June 30, 2026
				(RMB in thousands)
Cost of revenues		280			301		300		82			141
Research and development expenses		(270	)		73		259		(345	)		345
Selling and marketing expenses		364			624		748		164			269
General and administrative expenses		2,005			2,831		1,815		1,907			1,244
Total share-based compensation expenses		2,379			3,829		3,122		1,808			1,999


	For the six months ended
	June 30, 2025			June 30, 2026			June 30, 2026
	RMB			RMB			US$
Net cash used in operating activities		(67,876	)		(51,657	)		(7,613	)
Net cash used in investing activities		(1,324	)		(2,841	)		(419	)
Net cash generated from/(used in) financing activities		2,000			(100	)		(15	)
Effect of exchange rate on cash, cash equivalents and restricted cash		62			(7,382	)		(1,088	)
Net decrease in cash, cash equivalents and restricted cash		(67,138	)		(61,980	)		(9,135	)
Cash, cash equivalents and restricted cash at the beginning of period		522,162			481,088			70,904
Cash, cash equivalents and restricted cash at the end of period		455,024			419,108			61,769


	For the three months ended
	June 30, 2025			September 30, 2025			December 31, 2025			March 31, 2026			June 30, 2026			June 30, 2026
	RMB			RMB			RMB			RMB			RMB			US$
Revenues		148,554			131,617			126,315			107,943			134,765			19,862
Cost of revenues		(40,451	)		(32,773	)		(27,749	)		(29,935	)		(36,952	)		(5,446	)

Gross profit		108,103			98,844			98,566			78,008			97,813			14,416
Operating expenses:
Research and development expenses		(49,770	)		(41,469	)		(34,866	)		(27,559	)		(31,230	)		(4,603	)
Selling and marketing expenses		(38,413	)		(41,808	)		(44,066	)		(41,206	)		(47,141	)		(6,948	)
General and administrative expenses		(31,417	)		(31,698	)		(31,672	)		(28,088	)		(37,443	)		(5,518	)

Total operating expenses		(119,600	)		(114,975	)		(110,604	)		(96,853	)		(115,814	)		(17,069	)

Loss from operations		(11,497	)		(16,131	)		(12,038	)		(18,845	)		(18,001	)		(2,653	)
Interest income		2,226			1,744			1,502			1,261			1,370			202
Interest expense		—			(15	)		(15	)		(15	)		(15	)		(2	)
Other income (expense), net		387			7			1			294			(199	)		(29	)
Foreign exchange (loss) gain, net		(574	)		(2,151	)		(3,960	)		65			(1,278	)		(188	)

Loss before income tax		(9,458	)		(16,546	)		(14,510	)		(17,240	)		(18,123	)		(2,670	)
Income tax expenses		(244	)		(212	)		(876	)		(232	)		(287	)		(42	)

Net loss		(9,702	)		(16,758	)		(15,386	)		(17,472	)		(18,410	)		(2,712	)

Net loss attributable to Burning Rock Biotech Limited’s shareholders		(9,702	)		(16,758	)		(15,386	)		(17,472	)		(18,410	)		(2,712	)
Net loss attributable to ordinary shareholders		(9,702	)		(16,758	)		(15,386	)		(17,472	)		(18,410	)		(2,712	)
Loss per share for class A and class B ordinary shares:
Class A ordinary shares - basic and diluted		(0.09	)		(0.16	)		(0.15	)		(0.17	)		(0.17	)		(0.02	)
Class B ordinary shares - basic and diluted		(0.09	)		(0.16	)		(0.15	)		(0.17	)		(0.17	)		(0.02	)
Weighted average shares outstanding used in loss per share computation:
Class A ordinary shares - basic and diluted		90,357,970			90,416,619			87,444,109			87,871,026			91,279,393			91,279,393
Class B ordinary shares - basic and diluted		17,324,848			17,324,848			17,324,848			17,324,848			17,324,848			17,324,848
Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustments		(243	)		(1,724	)		(2,050	)		(3,143	)		(2,971	)		(438	)
Total comprehensive loss		(9,945	)		(18,482	)		(17,436	)		(20,615	)		(21,381	)		(3,150	)
Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders		(9,945	)		(18,482	)		(17,436	)		(20,615	)		(21,381	)		(3,150	)


	As of
	December 31, 2025		June 30, 2026		June 30, 2026
	RMB		RMB		US$
ASSETS
Current assets:
Cash and cash equivalents		478,392		416,818		61,431
Restricted cash		2,696		2,290		338
Accounts receivable, net		169,611		172,768		25,463
Contract assets, net		12,301		9,777		1,441
Inventories, net		48,576		34,131		5,030
Contract costs		8,399		5,597		825
Prepayments and other current assets		18,611		22,636		3,337

Total current assets		738,586		664,017		97,865
Non-current assets:
Property and equipment, net		31,099		31,808		4,688
Operating right-of-use assets		42,774		46,282		6,821
Intangible assets, net		284		233		35
Other non-current assets		7,632		8,271		1,219

Total non-current assets		81,789		86,594		12,763
TOTAL ASSETS		820,375		750,611		110,628


	As of
	December 31, 2025			June 30, 2026			June 30, 2026
	RMB			RMB			US$
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable		40,744			17,950			2,646
Deferred revenue		107,819			109,170			16,090
Accrued liabilities and other current liabilities		80,861			68,458			10,090
Customer deposits		592			592			87
Current portion of long-term borrowings		200			200			29
Current portion of operating lease liabilities		16,762			21,172			3,120
Total current liabilities		246,978			217,542			32,062

Non-current liabilities:
Long-term borrowings		1,700			1,600			236
Non-current portion of operating lease liabilities		24,458			22,140			3,263
Other non-current liabilities		11,975			12,248			1,805

Total non-current liabilities		38,133			35,988			5,304
TOTAL LIABILITIES		285,111			253,530			37,366

Shareholders’ equity:
Class A ordinary shares		120			126			19
Class B ordinary shares		21			21			3
Additional paid-in capital		5,010,060			5,013,867			738,953
Treasury stock		(57,193	)		(57,193	)		(8,429	)
Accumulated deficits		(4,255,607	)		(4,291,489	)		(632,487	)
Accumulated other comprehensive loss		(162,137	)		(168,251	)		(24,797	)
Total shareholders’ equity		535,264			497,081			73,262

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		820,375			750,611			110,628